GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Harbin Pharmaceutical Group Co Ltd (SHSE:600664) » Definitions » Return-on-Tangible-Asset

Harbin Pharmaceutical Group Co (SHSE:600664) Return-on-Tangible-Asset : 5.19% (As of Mar. 2024)


View and export this data going back to 1993. Start your Free Trial

What is Harbin Pharmaceutical Group Co Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Harbin Pharmaceutical Group Co's annualized Net Income for the quarter that ended in Mar. 2024 was ¥707 Mil. Harbin Pharmaceutical Group Co's average total tangible assets for the quarter that ended in Mar. 2024 was ¥13,613 Mil. Therefore, Harbin Pharmaceutical Group Co's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2024 was 5.19%.

The historical rank and industry rank for Harbin Pharmaceutical Group Co's Return-on-Tangible-Asset or its related term are showing as below:

SHSE:600664' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -9.21   Med: 2.95   Max: 5.64
Current: 3.36

During the past 13 years, Harbin Pharmaceutical Group Co's highest Return-on-Tangible-Asset was 5.64%. The lowest was -9.21%. And the median was 2.95%.

SHSE:600664's Return-on-Tangible-Asset is ranked better than
57.06% of 1083 companies
in the Drug Manufacturers industry
Industry Median: 1.61 vs SHSE:600664: 3.36

Harbin Pharmaceutical Group Co Return-on-Tangible-Asset Historical Data

The historical data trend for Harbin Pharmaceutical Group Co's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Harbin Pharmaceutical Group Co Return-on-Tangible-Asset Chart

Harbin Pharmaceutical Group Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.48 -9.21 3.14 3.70 2.98

Harbin Pharmaceutical Group Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.77 1.84 3.24 3.11 5.19

Competitive Comparison of Harbin Pharmaceutical Group Co's Return-on-Tangible-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Harbin Pharmaceutical Group Co's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Harbin Pharmaceutical Group Co's Return-on-Tangible-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Harbin Pharmaceutical Group Co's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Harbin Pharmaceutical Group Co's Return-on-Tangible-Asset falls into.



Harbin Pharmaceutical Group Co Return-on-Tangible-Asset Calculation

Harbin Pharmaceutical Group Co's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=395.263/( (12903.939+13594.763)/ 2 )
=395.263/13249.351
=2.98 %

Harbin Pharmaceutical Group Co's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=706.964/( (13594.763+13631.589)/ 2 )
=706.964/13613.176
=5.19 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2024) net income data.


Harbin Pharmaceutical Group Co  (SHSE:600664) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Harbin Pharmaceutical Group Co Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Harbin Pharmaceutical Group Co's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Harbin Pharmaceutical Group Co (SHSE:600664) Business Description

Traded in Other Exchanges
N/A
Address
Xi'an Street West, People 's Development Zone Baoan Road South, Heilongjiang Province, Harbin, CHN, 150018
Harbin Pharmaceutical Group Co Ltd is engaged in manufacturing, trading and research and development of pharmaceuticals. The company is organized into seven business segments - Antibiotics, Small-Molecular drug preparations, OTC and healthcare products, Modern Chinese medicines, Biopharmaceuticals, Animal vaccines, and medicine circulations. The company sells its products across China and fifty other countries. Some of its brands are - Hayao, Sanjing, Gaizhonggai, Hutong, and Shiyitang.
Executives
Lin Guo Ren senior management
Wang Hai Sheng senior management
Liu Bo senior management
Meng Xiao Dong senior management
Xu Hai Ying Directors, senior managers
Liang Chen senior management
Wang Peng Hao senior management
Xiao Qiang senior management
Wei Shuang Ying senior management
Zhou Xing senior management
Bian Ke Supervisors
Sha Mei senior management
Jian Shi Hui Zhu Xi Supervisors
Wang Zhi Fu Supervisors
Jiang Lu Director

Harbin Pharmaceutical Group Co (SHSE:600664) Headlines

No Headlines